Business Combinations and Contingent Consideration (Tables)

6 Months Ended

Jun. 30, 2016

Talon Therapeutics, Inc. [Member]

Change in Fair Value of Contingent Consideration Related to Acquisitions

	Fair Value of Talon CVR
December 31, 2015	$	1,377
Fair value adjustment for the six months ended June 30, 2016	554
June 30, 2016	$	1,931

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following:

Cash consideration	$	3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$	7,700

Melphalan license [Member]

Change in Fair Value of Contingent Consideration Related to Acquisitions

	Fair Value of Ligand Contingent Consideration
December 31, 2015	$	5,227
Fair value adjustment for the three months ended March 31, 2016	773
Payment to Ligand in April 2016	$	(6,000	)
June 30, 2016	$	—

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows:

EVOMELA IPR&D $ 7,700